RxKinetix: The Hits Keep Coming

Congratulations to Harry Ross and the entire RxKinetix team on the Endo Pharmaceuticals Holdings, Inc. (NASDAQ: ENDP) deal. The disclosed terms indicate Endo Pharma will pay a $20M up-front fee and will follow on with up to an additional $95M in clinical development and regulatory milestone payments.

Early indications are that RxKinteix, like Myogen, will remain in Colorado and continue to operate as a wholly owned subsidiary…more great news for Colorado bio.

RxKinetix's lead product is RK-0202, it is in clinical Phase II trials for the prevention of oral mucositis. Endo plans to conduct additional Phase II trials of RK- 0202 to continue to characterize the clinical profile of the product in head and neck cancer patients undergoing combination treatment of radiation and chemotherapy.

Importantly :-) CEO Harry Ross was also the first guest blogger to appear on Colorado Life Science Deal Flow, you can read his words of wisdom (here). Not only is Dr. Ross an accomplished physician, entrepreneur and investor he is also an incredibly accessible and caring individual.

With the caliber of persons such as Dr. Ross and the caliber of technology in Colorado it is only a matter of time before Colorado bio is uttered in the same breath as SF/SD and Boston.